About Tianjin Pharma
TIANJIN PHARMACEUTICAL HOLDINGS CO., LTD. advocates the corporate core values of "Love, Integrity and Power", and has been working to improve people's health and well-being, protect people's lives, benefit the public and safeguard people's happy life, and is committed to building a market-driven, technology-empowered leader in the health industry.
Our strategic growth areas
Green traditional Chinese medicine
In the track of green traditional Chinese medicine, we will, with Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (ticker symbol: SH600329) as the core enterprise, integrate plantation and processing of herbs and R&D, production and commerce of pharmaceuticals, covering the whole industrial chain of traditional Chinese medicine.
Chemical and biological pharmaceuticals
In the track of chemical and biological pharmaceuticals, we will, with Tianjin Tianyao Pharmaceuticals Co., Ltd. (ticker symbol: SH600488) as the core enterprise, are committed to building a track pattern of integrated R&D, production and sales of APIs and preparations, relying on several production bases in Tianjin Binhai New Area, Xiangyang, Hubei Province, and Yong Guang, Hebei Province.
In the track of medical devices, we will, with MEDA Co., Ltd. and NewScen Coast Bio Pharmaceutical Co., Ltd. as the core enterprises, strive to improve the independent R&D capabilities and product technology level and build an advantageous high-end product platform.
Taking Jinyao Pacific Pharmaceutical Co., Ltd. as the leader, we will cooperate with Zhongxin Pharmaceutical Plant to create a “variety + network + channel” model, apply international advanced warehousing management system and modern information technology to create an efficient drug circulation platform, and realize the “seamless connection” between the logistics industry and drug manufacturers, suppliers, downstream customers and related units.
With Tianjin Yumeijing Group Co., Ltd. and Tianjin Puguang Medical Materials Manufacturing Co., Ltd. as the core enterprises, we will professionally develop various special products to meet the health needs of consumers and protect the health of you and your family by relying on the Group Company’s advantages in R&D, production and quality inspection of pharmaceuticals.
Taking Jinyao Asset Management Co., Ltd. as the main body, we will build a group asset and investment management platform to lay a good foundation for future capital operation.
With Tianjin Pharmaceutical Design Institute Co., Ltd. and Tianjin Pharmaceutical Group Finance Co., Ltd. as the core enterprises, we will be engaged in medical engineering design, group finance and fund management to serve the high-quality development of the Group Company.
In the spotlight
-
- 07.31 2024
News :Tianjin Pharma received CEP certificate for betterson dipropionate raw material to broaden the scope of the international market
- 07.31 2024
-
- 06.24 2024
News :Tianjin Pharma won the "CPHI China Leading Enterprise Award for International Pharmaceutical Products"
- 06.24 2024
-
- 02.05 2024
News :The group's invention patent is authorized in Europe!
- 02.05 2024
-
-
Da Ren Tang (600329.SH)
-
32.58
-0.54-1.63%
2023/10/13 15:00:01
-
-
-
TJ PHARMA (600488.SH)
-
5.18
-0.54-1.63%
2023/10/13 15:00:01
-